

Real-world evidence of the efficacy of Mechanical Thrombectomy in the UK: Results from nationwide stroke registry and comparison with the HERMES metanalysis

Youssef Hbid* ¹, Mohammad Yadegarfar ¹, Kaili Stanley ¹, Ajay Bhalla ^{1,2}, Abdel Douiri ¹, Charles Wolfe ¹, Martin James ^{3,4}

¹ King's College London Guy's Campus, School of Life Course & Population Sciences, London, United Kingdom, ² Guy's and St Thomas' NHS Foundation Trust, London, UK, ³ Royal Devon & Exeter Hospital, Stroke, Exeter, UK, ⁴ University of Exeter Medical School, Medical School, Exeter, UK.
CONTACT: Youssef.hbid@kcl.ac.uk

INTRODUCTION

Randomized controlled trials have shown mechanical thrombectomy (MT) to be a highly effective and safe treatment in experienced centres. Large scale national disease registry data can establish whether the same benefits accrue from real-world clinical implementation. We report MT outcomes from the UK national registry (SSNAP) in comparison with the meta-analysis from the HERMES collaboration.



METHODS

- Data were extracted from the national SSNAP register from all 26 UK centres providing MT for patients admitted between 2016 and 2022.
- 540,682 patients were recorded in SSNAP, of which 8,381 were treated with MT (1.5%).
- Primary outcome is functional independence measured using the modified Rankin Scale (mRS 0-2) at 90 days or discharge.
- Descriptive statistics were used to analyse patient characteristics and subgroups.

RESULTS

Treatment and outcome details	N	SSNAP	N	HERMES	P value
Treatment with tPA	8381	4630 (55%)	634	526 (83%)	<0.001
Treatment with tPA within 180 min	8381	4589 (54%)	634	442 (70%)	<0.001
Onset to tPA (min)	4630	135 [105 ; 178.8]	598	100 [75 ;133]	0.5
Onset to arterial puncture (min)	8381	296 [219 ; 440]	607	238 [180 ; 302]	<0.001
Onset to reperfusion (min)	7779	322 [242 ; 473]	385	285 [210 ; 362]	<0.001
Arrival to arterial puncture (min)	8381	169 [110 ; 245]	602	104 [74 ; 148]	<0.001
Arterial puncture to Reperfusion (min)	7177	20 [13 ; 31]	384	44 [27 ; 64.5]	<0.001
Arrival to reperfusion (min)	7177	193 [133 ; 271]	383	148 [112 ; 197]	<0.001
NIHSS 0-2 at 24h	8256	1726 (21%)	615	129 (21%)	0.96
NIHSS at 24h	8256	10.9 (9.3)	615	10.4 (8.7)	0.42
Change in NIHSS from baseline to 24h	8256	-5.4 (9.0)	615	-6.4 (8.2)	0.42
mTICI score 2b/3	8381	6743 (80%)	570	402 (70.5%)	<0.001
Modified Rankin scale 0-2	8381	3100 (37%)	633	291 (46%)	<0.001
Modified Rankin scale 3-5	8381	3939 (47%)	633	245 (38.7%)	<0.001
Discharge mortality	8381	1340 (16%)	633	97 (15.3%)	0.70

Figure 1: Casemix comparison



CONCLUSIONS

- The UK MT-treated population has some significant differences in baseline characteristics, bridging thrombolysis use and workflow compared to the original trials included in HERMES, but pre-treatment stroke severity was similar.
- Procedural and short-term outcomes (NIHSS at 24 hrs) are similar between the datasets.
- Real-world implementation of MT in the UK has resulted in similar case-fatality rate to that seen in HERMES. Although median mRS (at discharge [SSNAP] or 90 days [HERMES]) cannot be directly compared, a smaller proportion of UK patients achieved an 'independent' outcome (mRS 0-2).

Reference

Goyal, M., HERMES collaborators (2016). Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. *Lancet* (London, England), 387(10029), 1723-1731. [https://doi.org/10.1016/S0140-6736\(16\)00163-X](https://doi.org/10.1016/S0140-6736(16)00163-X)

Acknowledgment

Thank you to all individuals and organisations that participate in SSNAP, which is funded by NHS England and NHS Wales